Adaptive evolution and global spread of macrolide-resistant *Bordetella pertussis* during the post-pandemic pertussis resurgence

Haodong Zhang[a,b, 1], Zhihua Kang[c,1], Yingying Zhang[d,1],Yuanbin Yang[e,1], Huiwen Li[a,b], Naike Wang [f], Jiancheng Wang[f], Fuxing Jiao[f], Shanwei Tong[f], Bingsong Wang[g], Song Gao[h], Chengpei Ni[h], Xiaolu Shi[i], Shuang Wu[i], Simo Huang[j], Danni Bao[k], Qiushui He[l,m,n], Chuanqing Wang[a,b,*], Zhi Ruan[d,o,p*], Pan Fu[a,b*], Chao Yang[f,*]

[a.] Laboratory of Microbiology, Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China

[b.] Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China

[c.] Department of Laboratory Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

[d.] Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

[e.] Department of Microbiological Testing, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, China

[f.] Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

[g.] Pediatric Respiratory Department, Wuhu No.1 People's Hospital, Wuhu, Anhui, China

[h.] The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi, China

[i] Shenzhen Center for Disease Control and Prevention, Shenzhen, China

[j.] Department of Clinical Laboratory, Seventh Medical Center, PLA General Hospital, Beijing, China

[k.] Department of Clinical Laboratory, Sanmen People's Hospital, Taizhou, China

[l.] Institute of Biomedicine, University of Turku, Turku, Finland

[m.] InFLAMES Research Flagship Centre, University of Turku, Turku, Finland

[n.] European Union (EU) Reference Laboratory for Diphtheria & Pertussis (EURL-PH-DIPE), Turku, Finland

[o.] Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, China

[p.] Zhejiang Provincial Engineering Research Center of Innovative Instruments for Precise Pathogen Detection, Hangzhou, China

[1] Those authors contribute equally

*Correspondence

Chuanqing Wang: chuanqing523@163.com; Zhi Ruan: r_z@zju.edu.cn;

Pan Fu: fup1028@163.com; Chao Yang: cyang@siii.cas.cn

Abstract

Pertussis resurgence following the COVID-19 pandemic remains poorly understood. Here, we integrate global surveillance data with 8,117 *Bordetella pertussis* genomes from 35 countries to investigate the role of pathogen evolution. We identify substantial shifts in *B. pertussis* populations in China and Australia, alongside marked changes in multiple European countries. In China, resurgence is driven by the rapid expansion of a single macrolide-resistant clone, MR-MT28. Elsewhere, resurgence involves diverse, pre-pandemic polyphyletic strains. Australia and Europe show convergent antigenic changes, including a decline in pertactin-deficient strains, a rise in *prn2* alleles, and rising macrolide resistance. Notably, we detect post-pandemic international dissemination of MR-MT28 across four continents, with non-Chinese isolates belonging predominantly to a pertactin-deficient subclone. These findings reveal convergent and region-specific strain replacement, antigenic evolution and macrolide resistance, highlighting the key role of adaptive evolution in the global pertussis resurgence. The emergence and global spread of MR-MT28 underscore the urgent need for coordinated global surveillance.

Introduction

Pertussis, a highly contagious respiratory disease primarily caused by *Bordetella pertussis*, declined globally following the introduction of whole-cell and acellular vaccines[1,2]. Despite sustained high vaccination coverage, many countries have observed a resurgence over the past two decades, with a marked increase post-COVID-19 pandemic[3–5].

According to the World Health Organization (WHO), following a sharp decline during the COVID-19 pandemic (2020–2022), global pertussis cases rose substantially post-pandemic (2023–2024), exceeding 800,000 notifications worldwide in 2024 —over at least four times higher than the pre-pandemic average (**figure 1A**). In Asia, China and South Korea reported >10-fold and >20-fold increases, respectively[6–8]. Several European countries, including France, Czechia and Denmark, recorded historically high incidence[9–12]. Similar surges were observed in Australia[13] and the United States[4] (**figure 1B**).

Multiple factors underlie this resurgence, including immunity debt from pandemic-related non-pharmaceutical interventions, waning vaccine-induced immunity, and adaptive evolution of *Bordetella pertussis*[2–7]. Over recent decades, *B. pertussis* has undergone notable genetic shifts, including the emergence and prevalence of strains with *ptxP3* alleles potentially associated with increased virulence[14], and pertactin (PRN)-deficient variants, which may evade vaccine-induced immunity[15]. In parallel, the emergence of macrolide-resistant *B. pertussis* (MRBP), particularly its predominance in China, has raised additional concern regarding potential transmission and treatment failures[16–19].

Of particular concern is the *ptxP3* MR-MT28 clone. It has been proposed as a major driver of China's post-pandemic resurgence due to its combined features of vaccine escape and antimicrobial resistance[18,20]. Notably, this clone has been recently detected in France[11,12] and Australia[13], raising concerns of international dissemination. Although the post-pandemic resurgence of pertussis in China appears closely associated with the expansion of the MR-MT28 clone, integrated analyses of dynamics of circulating *B. pertussis* strains and rising incidence of pertussis before, during and after the pandemic at global level have been not performed.

In this study, we investigated the genomic evolution of *B. pertussis* in the context of the global post-pandemic resurgence. We found that lineage composition, vaccine antigen profiles, and MRBP prevalence underwent substantial shifts in several regions in parallel with the rising pertussis burden, providing evidence that adaptive evolution of *B. pertussis* is one key contributor to the recent global resurgence. Our analysis highlights that the MR-MT28 clone, which drove the post-pandemic resurgence in China, has now spread to other three continents, underscoring the urgent need for coordinated global surveillance.

Results

Global genomic diversity and population structure of *B. pertussis*

We analysed 8,117 high-quality (completeness >95%, contamination <5%) *B. pertussis* genomes, including 249 newly sequenced strains from six regions in China. These genomes

97 spanned 35 countries across six continents. Four continents and five countries each had more
98 than ten genomes from both pre-pandemic and during/post-pandemic periods, enabling
99 temporal and geographical comparisons (**Fig. 2A**; Supplementary Fig. 1).
100
101 A core-genome SNP-based phylogenetic tree was constructed to characterise the global
102 population structure of *B. pertussis* (**Fig. 2B**). The phylogentic tree revealed that 99.6%
103 (8087/8117) of isolates belonged to lineage IIb[30], which could be further divided into three
104 major sublineages based on *ptxP* and *fim3* genotypes: *ptxP1/fim3-1* (17%, n=1364),
105 *ptxP3/fim3-1* (60%, n=4812), and *ptxP3/fim3-2* (22%, n=1816). The difference between *fim3-*
106 *1* and *fim3-2* alleles is a point mutation of C260A causing an amino acid change (Ala87Glu),
107 and the difference between *ptxP1* and *ptxP3* is a point mutation of C to A in promoter of
108 pertussis toxin gene.
109
110 The MRBP-associated A2047G mutation in 23S rRNA gene were detected in 59% (811/1364)
111 of *ptxP1/fim3-1*, 11% (519/4812) of *ptxP3/fim3-1* and 0.3% (5/1817) of *ptxP3/fim3-2* strains.
112 Nearly all (99%, 513/519) *ptxP3/fim3-1* MRBP strains belonged to the MR-MT28 clone (**Fig.**
113 **2B**), which was predominantly identified in China[20].
114
115 **Lineage dynamics and variation in vaccine antigen and antibiotic resistance profiles**
116 Post-pandemic increases in pertussis were accompanied by convergent and region-specific
117 shifts in lineage composition, vaccine antigen profiles, and macrolide resistance (**Fig. 3,**
118 Supplementary Fig. 2).
119
120 In Asia (n=2023), primarily represented by China (n=1645), the *ptxP3/fim3-1* sublineage
121 expanded rapidly during and after the pandemic, alongside a marked rise in MRBP frequency
122 and substantial shifts in antigen profiles (**Fig. 3**). This transition was driven by the emergence
123 and rapid expansion of the MR-MT28 clone. MR-MT28 (n=513) carried either *ptxP3/fim3-*
124 *1/prn150* (74%, 382/513) or *ptxP3/fim3*-1 with predicted PRN-deficiency (25%, 129/513)
125 profiles, becoming the dominant clone (99%) post-pandemic in China (**Fig. 2B, Fig. 3**). This
126 clonal replacement also shifted the MRBP composition, from a pre-pandemic predominance

127 of *ptxP1/fim3-1* strains (87%, 774/891) to *ptxP3/fim3-1* (92%, 386/418) post-pandemic (**Fig.**
128 **3B**). In line with the dominance of a single clone, the genetic diversity of post-pandemic
129 strains (median SNP distance: 8) was significantly decreased compared to that of pre-
130 pandemic strains (median SNP distance: 31; **Fig. 2C**).
131
132 Similarly, in Oceania (n=489), mainly represented by Australia (n=445), substantial post-
133 pandemic shifts were observed in sublineage distribution and antigen gene composition,
134 accompanied by an increase in MRBP prevalence (**Fig. 3**). Based on this genomic analysis,
135 MRBP prevalence notably reached 23% (9/40) post-pandemic—an unexpectedly high
136 frequency given the previous rarity of MRBP outside China[19], and this rise was also
137 associated with the introduction of the MR-MT28 clone. Unlike Asia, changes in sublineage
138 and antigen gene profiles were largely driven by the rise of *ptxP3/fim3-2* sublineage and *fim3-*
139 *2* and *prn2* alleles, along with a decreased frequency of predicted PRN-deficient strains (**Fig.**
140 **3**).
141
142 Post-pandemic strains in Oceania remained genetically diverse, with *ptxP3/fim3-2* and
143 *ptxP3/fim3-1* sublineages present at 45% (18/40) and 53% (21/40), respectively. Accordingly,
144 genetic diversity remained relatively stable post-pandemic. Phylogenetic analysis showed that
145 close relatives of most post-pandemic strains were already circulating before the pandemic,
146 with the exception of MR-MT28, suggesting that the resurgence in Oceania might be driven
147 by the expansion of locally pre-existing lineages (**Fig. 2B, Fig. 3**).
148
149 In Europe (n=2595), mainly represented by France (n=1308) and Belgium (n=429), noticeable
150 post-pandemic changes were observed in the vaccine antigen gene *prn*. As in Australia, the
151 frequency of the *prn2* allele increased post-pandemic, while the frequency of predicted PRN-
152 deficient strains decreased (**Fig. 3**). One MR-MT28 strain was detected in France in 2024.
153
154 Overall genetic diversity in Europe did not significantly decline post-pandemic, although two
155 dominant clones (Europe clone 1 and 2, accounting for 65% of post-pandemic strains) were
156 identified (**Fig. 2B**). Both clones were already present pre-pandemic, indicating continued

157 transmission of locally endemic strains. However, this varied by country—for instance, post-
158 pandemic strains in Belgium showed significantly reduced diversity, with 70% (64/91)
159 belonging to Europe clone 2 (**Fig. 2B,C**).
160
161 In North America (n=2,832), primarily represented by the United States (n=2,798), strain
162 dynamics remained relatively stable. The North America clone 1, prevalent pre-pandemic,
163 remained dominant post-pandemic (67%, 69/103), continuing to drive endemic circulation
164 (**Fig. 2B**). One MR-MT28 strain was identified in the United States in 2024.
165
166 **Evolutionary dynamics and global spread of the MR-MT28 clone**
167 The MR-MT28 clone was detected in four countries (China, Australia, France, and the United
168 States) across four continents post-pandemic (**Fig. 4A, B**), indicating its potential for global
169 dissemination. We therefore investigated its evolutionary origin and patterns of international
170 spread.
171
172 Phylogenetic analysis suggested that MR-MT28 evolved from the MS-MT28 lineage, which
173 was primarily identified in Europe and North America pre-pandemic (**Fig. 4C, D**). Although
174 MR-MT28 has become dominant in eastern China post-pandemic, it remains at relatively low
175 frequency in western regions (**Fig. 4B**). Molecular clock analysis estimated the emergence of
176 MR-MT28 around 2016 (95% CI: 2014–2018), most likely originating in China, where it now
177 predominates. Consistent with the observed rise in MR-MT28 cases and its geographic
178 expansion, its effective population size increased sharply post-pandemic—more than 1,000-
179 fold in 2024 compared to 2021 (**Fig. 4E**).
180
181 Compared to its ancestor MS-MT28, the MR-MT28 clone harbours two defining mutations:
182 the macrolide resistance-associated A2047G mutation in the 23S rRNA gene, and a
183 synonymous G1959A mutation in *BP0685* (dehydrogenase/oxidase). The novel antigen allele
184 *prn150*, found predominantly in MR-MT28, was also present in one MS-MT28 strain from
185 Shanghai, China.
186

187 Two emerging subclones were identified within MR-MT28 (**Fig. 4C, D**). Subclone 1 (SC1),
188 estimated to have emerged around 2019, is characterised by predicted PRN deficiency, a
189 nonsynonymous mutation in *BP3197* (G287T; Arg96Leu; NAD(P)-dependent
190 oxidoreductase), and, in a subset of strains, a mutation in *BP0026* (G370T; Ala124Ser;
191 thiolase family protein). Notably, most (7/9) MR-MT28 strains detected in Australia and the
192 single French isolate belonged to SC1, suggesting enhanced transmission potential, possibly
193 associated with immune evasion.
194
195 Subclone 2 (SC2) harboured three distinct mutations: *BP2642A* (C664T; Pro222Ser; ABC
196 transporter ATP-binding protein), *BP3467* (G1621A; Asp541Asn; AsmA family protein), and
197 a synonymous mutation in *BP3491* (C318A; NAD(P)/FAD-dependent oxidoreductase).
198 Intriguingly, both subclones independently accumulated mutations in NAD(P)-dependent
199 oxidoreductase genes (*BP3197* in SC1 and *BP3491* in SC2), suggesting convergent
200 adaptation.
201
202 **Discussion**
203 The global resurgence of pertussis appears to be multifactorial, shaped by both host-related
204 and pathogen-related drivers[2–7]. Although the impact of host-relalted factors, such as non-
205 pharmaceutical interventions and waning immunity, are difficult to quantify, genomic
206 surveillance enables comprehensive characterisation of pathogen evolution. In this study, we
207 systemically analyzed all available sequences of *B. pertussis* strains in the world and
208 compared the results with incidences of pertussis before, during and after the COVID-19
209 pandemic. Our findings reveal substantial or noticeable post-pandemic shifts in *B. pertussis*
210 lineage composition, vaccine antigen profiles, and macrolide resistance across three
211 continents, with the most pronounced changes observed in China and Oceania.
212
213 In particular, we observed the rise of genotypes carrying mutations associated with antibiotic
214 resistance, vaccine escape (PRN-deficient strains), and potential increases in virulence (e.g.,
215 *ptxP3* strains). The clearest evidence of such adaptive evolution was observed in China, where
216 the *ptxP3* MR-MT28 clone, encoding a novel *prn150* allele, emerged as the dominant post-

pandemic clone. This clone, capable of causing infections among older children and vaccinated individuals, was most likely the primary driver of the post-pandemic pertussis upsurge in China[18,20].

Patterns of strain replacement and antigenic variation exhibited both convergent and divergent trends across continents. First, increased MRBP prevalence and higher frequencies of the *ptxP3* and *prn150* alleles were observed in both China and Australia post-pandemic, largely driven by the expansion of the MR-MT28 clone. Second, PRN-deficient strains declined in prevalence in Europe, Australia, and the United States after the pandemic, accompanied by a concurrent rise in the *prn2* allele[31]. Third, the *fim3-1* allele, already predominant before the pandemic, further increased in frequency in China, Europe, and the United States post-pandemic.

Region-specific trends revealed distinct adaptive trajectories. In China, the post-pandemic resurgence was driven by the clonal expansion of MR-MT28, in contrast to the polyphyletic strain composition observed in other regions. Notably, the prevalence of PRN-deficient strains uniquely increased in China post-pandemic, despite being rarely reported pre-pandemic and declining in frequency in many other countries[11,32,33]. This suggests that PRN deficiency may confer context- and time-dependent advantages, potentially shaped by regional vaccine formulations, the duration of vaccine use, and extent of exposure to pertussis in the population. In Australia, the frequency of the *fim3-2* allele uniquely rose post-pandemic. This allele had shown a global increase beginning in 1996, coinciding with the transition from whole-cell to acellular vaccines[30]. However, its global frequency has gradually declined since 2020 for reasons that remain unclear. The *fim3-2* allele has also been reported to be associated with enhanced biofilm formation[34]. Together, these findings may reflect region-specific selective pressures and potential local adaptation in China and Australia.

Despite the long-standing predominance of *ptxP1* MRBP strains in China for over a decade, they remain rarely detected elsewhere[16–19]. In contrast, *ptxP3* MR-MT28 clone has been identified across four continents, suggesting that it may possess distinctive features

247 facilitating international spread. Indeed, the *ptxP3* strains appeared in Australia, Europe and
248 the United States in 1990s and became prevalent since then. Our genomic analysis revealed a
249 notable post-pandemic rise in MRBP prevalence in Australia, reaching 23% post-pandemic.
250 This was further supported by targeted culture-independent sequencing screening, which
251 estimated MRBP prevalence of 4.4%[13]. In addition to the MR-MT28 strain identified in this
252 study from France, a recent French study showed that overall MRBP accounted for 2.8%
253 (17/593) of the tests (culture and qPCR) in 2024. Phylogenetic analysis revealed that the 14
254 MRBP belong, together with isolates from China, to a cluster of 349 MRBP isolates. All 14
255 MRBP carried *ptxP3*, and 13 of them were PRN-deficient[11,12]. Moreover, MRBP strains have
256 recently been identified in other European countries such as Finland[33]. Thus, the geographic
257 range of MR-MT28 described here only represents a minimum estimate.
258
259 Most MR-MT28 strains detected in Australia and France were PRN-deficient, suggesting that
260 PRN deficiency may confer additional advantages, such as enhanced vaccine escape potential.
261 Together, these findings indicate that MR-MT28 represents a significant risk for global
262 dissemination and underscore the urgent need for strengthened international surveillance,
263 particularly targeting PRN-deficient MR-MT28 strains.
264
265 This study has several limitations. First, the publicly available genomic data used for
266 contextualisation are subject to inherent sampling biases. Since the number of genomes
267 available across countries and continents varies substantially, the results should be interpreted
268 with caution. Second, recent genomic data from several regions, particularly the United States
269 and parts of Europe, are limited or unavailable for comparison. Third, the number of isolates
270 during the pandemic is very limited, which may affect our understanding of circulating strains
271 during that period. Finally, vaccination programmes, vaccine types used, and non-
272 pharmaceutical interventions varied across countries, and the resulting selection pressures in
273 different populations may differ accordingly.
274
275 In conclusion, our study provides genomic evidence that the adaptive evolution of *B.*
276 *pertussis*, through lineage replacement, antigenic variation, and antimicrobial resistance, has

played a significant role in the post-pandemic resurgence of pertussis. The emergence and international dissemination of the MR-MT28 clone represent a growing public health challenge, emphasising the need for coordinated global surveillance and updated vaccine strategies.

Methods

Pertussis case data

Pertussis case numbers were obtained from the WHO website (https://immunizationdata.who.int/global/wiise-detail-page/pertussis-reported-cases-and-incidence). For countries or regions with incomplete WHO data, supplementary case counts were searched and sourced from national public health agencies, including the US Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC).

Genome collection and sequencing

We analysed a total of 8,368 non-redundant *B. pertussis* genomes with unique Biosample accession numbers, comprising 8112 publicly available genomes and 249 newly sequenced isolates. Public genomes were retrieved from the NCBI Sequence Read Archive (SRA) and GenBank, with isolation year and country extracted from BioSample metadata. Newly sequenced isolates were collected from six regions in China: Shanghai (n=42), Zhejiang (n=165), Anhui (n=7), Jiangsu (n=3), Sichuan (n=19), and Guangdong (n=13). Whole-genome sequencing for newly sequenced isolates was performed on the Illumina NovaSeq platform. Newly generated sequencing data are available in the NCBI SRA under accession number PRJNA1288341.

Raw sequencing reads were quality-trimmed using Trimmomatic v0.39[21]. Genome assembly was conducted using the shovill v1.1.0 pipeline (https://github.com/tseemann/shovill). Assembly quality was assessed using CheckM v1.1.3[22]. Only high-quality genomes (completeness >95%, contamination <5%) were retained in following analysis. Putative mutator strains indicated by abnormal tree branches were also removed from analysis.

307

308 After genome quality control, a total of 8117 high-quality genomes (Supplementary Table 1)
309 were used in the analysis, includes isolates collected between 1900 and 2024 from 35
310 countries across six continents: Europe (16 countries), Asia (6), North America (5), Africa (4),
311 Oceania (2), and South America (2).

312

313 **Phylogenetic and temporal analysis**

314 Core-genome single nucleotide polymorphisms (SNPs) were identified using Snippy v4.6.0
315 (https://github.com/tseemann/snippy), based on raw reads or assemblies where reads were
316 unavailable, with *B. pertussis* Tohama I (NC_002929.2) as the reference. SNPs within
317 repetitive regions were excluded as previously described[23]. Maximum-likelihood phylogenies
318 were constructed using FastTree v2.1.10[24] (all strains) or RAxML-NG v1.0.1[25] with the
319 GTR+Γ model (MR-MT28 clone).

320

321 Time-resolved phylogenies and effective population size dynamics were inferred using
322 BEAST v1.10.4[26]. We applied GTR+Γ substitution model and used isolation date (years) for
323 tip date calibration. Six combinations of molecular clocks (strict and uncorrelated relaxed
324 clock) and coalescent tree models (constant size and Bayesian Skyline and Skygrid) were
325 tested and Skygrid model were the best fit based on path sampling and steppingstone
326 sampling analysis. We ran ten independent Markov chain Monte Carlo chains for 30 million
327 steps, sampling every 3,000 steps. The results of different runs were combined to generate the
328 maximum clade credibility trees using TreeAnnotator v1.10.4. Effective population size
329 dynamics was inferred using Tracer v1.7.1[27].

330

331 **Vaccine antigen and macrolide resistance profiles**

332 Vaccine antigen alleles were assigned by comparison with the curated *Bordetella* allele
333 database on BIGSdb-Pasteur[28]. So far the only mechanism causing macrolide resistance has
334 been the point mutation of A2047G in the 23S rRNA gene of *B. pertussis*. Therefore, MRBP
335 strains carrying the A2047G mutation were detected using BLASTn. Strains were classified
336 as PRN-deficient if they carried incomplete or disrupted *prn* coding sequences or promoters

(BLASTn or TBLASTn coverage <99%), based on criteria defined by Lefrancq et al[29].

Data availability

Accession numbers for the publicly available genome sequences and associated metadata can be found in appendix and Zenodo (DOI:10.5281/zenodo.15900428). Newly sequenced genomes in this study are available from the National Centre for Biotechnology Information database under BioProject PRJNA1288341.

Acknowledgments

This work was supported by grants from National Key Research and Development Program of China (2022YFC2304700), National Natural Science Foundation of China (82202567, 32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences (2022278), and Shanghai Rising-Star Program (23QA1410500), Zhejiang Provincial Science and Technology Program for Disease Prevention and Control (2025JK139), Sigrid Juselius Foundation (240045) and Tampere Tuberculosis Foundation (26006205).

Author contributions

P.F., C.W. and Y.C. contributed to the conception of this project. Z.R., Y.Z., P.F., Z.K., Y.Y. B.W., D.B., S.G., C.N., X.S., S.W., S.H. were responsible for collection of strains and metadata. H.Z., C.Y., H.L., N.W., J.W., F.J., S.T. performed bioinformatics analysis of whole genome sequence data. Y.C., P.F. and Q.H. prepared the manuscript. All authors contributed to the interpretation of results and critical review of the manuscript.

Competing interests

We declare no competing interests.

Reference

1. Kapil, P. & Merkel, T. J. Pertussis vaccines and protective immunity. *Current Opinion in Immunology* vol. 59 72–78 (2019).

2. Domenech de Cellès, M. & Rohani, P. Pertussis vaccines, epidemiology and evolution.

367 *Nat Rev Microbiol* **22**, 722–735 (2024).

368 3. Locht, C. Pertussis before, during and after Covid-19. *EMBO Mol Med* **17**, 594-598–
369 598 (2025).

370 4. Kang, H. M., Lee, T.-J., Park, S. E. & Choi, S.-H. Pertussis in the Post-COVID-19
371 Era: Resurgence, Diagnosis, and Management. *Infect Chemother* **57**, 13–30 (2025).

372 5. Bricks, L. F., Vargas-Zambrano, J. C. & Macina, D. Epidemiology of Pertussis After
373 the COVID-19 Pandemic: Analysis of the Factors Involved in the Resurgence of the
374 Disease in High-, Middle-, and Low-Income Countries. *Vaccines* **12**, (2024).

375 6. Liu, Y., Yu, D., Wang, K. & Ye, Q. Global resurgence of pertussis: A perspective from
376 China. *Journal of Infection* **89**, (2024).

377 7. Mengyang, G., Yahong, H., Qinghong, M., Wei, S. & Kaihu, Y. Resurgence and
378 atypical patterns of pertussis in China. *Journal of Infection* **88**, (2024).

379 8. Lee, H. *et al.* Resurgence of Pertussis in the Gyeongnam Region of South Korea in
380 2023 and 2024. *Vaccines (Basel)* **12**, (2024).

381 9. Nordholm, A. C. *et al.* Pertussis epidemic in Denmark, August 2023 to February 2024.
382 *Eurosurveillance* **29**, 2400160 (2024).

383 10. Monchausse, T. *et al.* Clinical characteristics of cases during the 2024 pertussis
384 epidemic in France, January 2024 to December 2024. *Vaccine* **51**, 126862 (2025).

385 11. Rodrigues, C. *et al.* Resurgence of Bordetella pertussis, including one macrolide-
386 resistant isolate, France, 2024. *Eurosurveillance* **29**, 2400459 (2024).

387 12. Bouchez, V., Lefrancq, N., Toubiana, J., Rodrigues, C. & Brisse, S. Microbes know no
388 borders: importation of macrolide-resistant Bordetella pertussis into France in 2024.
389 *Clinical Microbiology and Infection* (2025).

390 13. Fong, W. *et al.* Targeted Culture-Independent Sequencing Identifies Emergence of
391 Macrolide-Resistant Bordetella Pertussis in Australia. *medRxiv* (2024).

392 14. Mooi, F. R. *et al.* Bordetella pertussis strains with increased toxin production
393 associated with pertussis resurgence. *Emerg Infect Dis* **15**, (2009).

394 15. Ma, L., Caulfield, A., Dewan, K. K. & Harvill, E. T. Pertactin-deficient Bordetella
395 pertussis, vaccine-driven evolution, and reemergence of pertussis. *Emerg Infect Dis*
396 **27**, (2021).

397 16. Wu, X. *et al.* A Cross-Sectional Study Revealing the Emergence of Erythromycin-
398 Resistant Bordetella pertussis Carrying ptxP3 Alleles in China. *Front Microbiol* **13**,

399 (2022).

400 17. Fu, P. *et al.* Emergence and spread of MT28 ptxP3 allele macrolide-resistant
401 Bordetella pertussis from 2021 to 2022 in China. *International Journal of Infectious*
402 *Diseases* **128**, 205–211 (2023).

403 18. Fu, P. *et al.* Molecular Evolution and Increasing Macrolide Resistance of Bordetella
404 pertussis, Shanghai, China, 2016–2022. *Emerg Infect Dis* **30**, 29 (2024).

405 19. Feng, Y. *et al.* Emerging macrolide resistance in Bordetella pertussis in mainland
406 China: Findings and warning from the global pertussis initiative. *The Lancet Regional*
407 *Health-Western Pacific* **8**, 98 (2021).

408 20. Fu, P. *et al.* Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by
409 ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China. *Clinical*
410 *Microbiology and Infection* **30**, 1439–1446 (2024).

411 21. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina
412 sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

413 22. Parks, D. H., Imelfort, M., Skennerton, C. T., Hugenholtz, P. & Tyson, G. W. CheckM:
414 Assessing the quality of microbial genomes recovered from isolates, single cells, and
415 metagenomes. *Genome Res* **25**, 1043–1055 (2015).

416 23. Yang, C. *et al.* Outbreak dynamics of foodborne pathogen Vibrio parahaemolyticus
417 over a seventeen year period implies hidden reservoirs. *Nat Microbiol* **7**, 1221–1229
418 (2022).

419 24. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 – Approximately Maximum-
420 Likelihood Trees for Large Alignments. *PLoS One* **5**, e9490 (2010).

421 25. Kozlov, A. M. *et al.* RAxML-NG: A fast, scalable and user-friendly tool for maximum
422 likelihood phylogenetic inference. *Bioinformatics* (2019).

423 26. Drummond, A. J. & Rambaut, A. BEAST: Bayesian evolutionary analysis by sampling
424 trees. *BMC Evol Biol* **7**, (2007).

425 27. Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior
426 summarization in Bayesian phylogenetics using Tracer 1.7. *Syst Biol* **67**, (2018).

427 28. Bridel, S. *et al.* A comprehensive resource for Bordetella genomic epidemiology and
428 biodiversity studies. *Nat Commun* **13**, (2022).

429 29. Lefrancq, N. *et al.* Global spatial dynamics and vaccine-induced fitness changes of
430 *Bordetella pertussis*. *Sci Transl Med* **14**, 3253 (2022).

30. Bart, M. J. *et al.* Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. *mBio* **5**, (2014).

31. Barkoff, A. M. *et al.* Surveillance of circulating bordetella pertussis strains in Europe during 1998 to 2015. *J Clin Microbiol* **56**, (2018).

32. Kastrin, T. *et al.* Pertussis epidemic in Slovenia in 2024;no pertactin-deficient or macrolide-resistant Bordetella pertussis isolates identified. *Clinical Microbiology and Infection* (2025).

33. Miettinen, M. *et al.* Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024. *Eurosurveillance* **29**, (2024).

34. Niinikoski, V., Barkoff, A. M., Mertsola, J. & He, Q. Bordetella pertussis isolates in Finland after acellular vaccination: serotype change and biofilm formation. *Clinical Microbiology and Infection* **30**, (2024).

445 **Figure legends**

446 **Figure 1. Global pertussis case numbers and incidence rates since 2000.** (A) Trends in
447 pertussis case numbers and incidence rates for the world and four continents. (B) Trends for
448 four countries with more than ten *B. pertussis* genomes from pre-, during-, and post-pandemic
449 periods. Incidence rates are shown per 100,000 population.

450

451 **Figure 2. Global population structure and resistance and antigenic profiles of *B.***
452 ***pertussis*.** (A) Annual number of high-quality genomes from four continents. (B) Maximum-
453 likelihood phylogenetic tree of global isolates annotated with geographic location and
454 macrolide resistance and vaccine antigen profiles. (C) Pairwise core-genome SNP distance
455 distributions within and between time periods (pre-, during-, and post-pandemic) for each
456 continent and representative countries.

457

458 **Figure 3. Temporal dynamics of *B. pertussis* lineages (A), macrolide resistance (B), and**
459 **antigenic (C) profiles.** Background colours indicate different time periods (pre-, during-, and
460 post-pandemic). Lines show the proportion of strains. Point sizes indicate the number of
461 genomes. Line and point colours represent each continent or country.

462

463 **Figure 4. Evolutionary dynamics and global dissemination of the MR-MT28 clone.** (A,
464 B) Geographic distribution of MR-MT28 strains post-pandemic (2023–2024) globally and
465 within China. Pie charts indicate the regional proportion of MR-MT28. (C) Maximum-
466 likelihood phylogeny of the MT28 clone. Tip colours represent country of origin. Outer rings
467 denote macrolide resistance (MR or MS) and *prn* allele profiles. (D) Time-calibrated
468 phylogeny of the MT28 clone with resistance status and *prn* allele profiles. Key time points,
469 genetic events, and 95% confidence intervals are indicated by arrows, triangles, and shaded
470 orange rectangles, respectively. (E) Temporal changes in the effective population size of the
471 MT28 clone inferred using Bayesian Skygrid analysis.


A
Pre-pandemic
During-pandemic
Post-pandemic
Incidence
Cases
North America
Asia
Europe
Oceania
Global
Case numbers (×1000)
Incidence rate (per 100000 population)
Year
B
China
France
Belgium
Australia
United States
Incidence
Cases
Case numbers (×1000)
Incidence rate (per 100000 population)
Year


A
Asia
Oceania
Europe
North America
Count
1000
500
0
2000
2012
2024
B
0.01
lineage II
IIb
IIa
lineage I
0.001
ptxP3/fim3-2
ptxP3/fim3-1
ptxP1/fim3-1
North America clone 1
Europe clone 1
MR-MT28
Europe clone 2
Asia
Oceania
Europe
North America
Resistance
Vaccine antigen gene
ptx
fim
ptxP
ptxA
ptxB
ptxC
ptxD
ptxE
fim2
fim3
fhaB
prn
Periods
Pre-pandemic
During-pandemic
Post-pandemic
Resistance
MR
MS
Antigen gene sequence typing
1
2
3
4
150
Others
Predicted PRN-deficient
C
Asia
Oceania
Europe
North America
Pre−pandemic
Post−pandemic
Pre- vs. Post -pandemic
0
50
100
China
Australia
France
Belgium
United States
Pairwise SNP Distance


Continent
Country
A
B
C
Proportion
ptxP1/fim3-1
ptxP3/fim3-1
ptxP3/fim3-2
MR
ptxP1-MR
ptxP3-MR
fim3-1
fim3-2
ptxP3
prn2
prn150
Predicted PRN-deficient
Asia
Oceania
Europe
China
Australia
Belgium
France
Continent Asia Oceania Europe North America
Country China Australia France Belgium United States
Time-span Pre-pandemic During-pandemic Post-pandemic
Sample size 10–30 30–100 >100


A
MR−MT28
Others
United States, 1/170
France, 1/82
China, 499/615
Australia, 9/41
B
Beijing, 3/3
Hebei, 0/1
Anhui Wuhu, 7/7
Jiangsu Wuxi, 3/3
Shanghai, 236/282
Zhejiang Jiaxing, 12/13
Zhejiang Ningbo, 142/143
Zhejiang Taizhou, 21/22
Zhejiang Yiwu, 33/63
Chengdu, 1/19
Guangdong, 41/59
C
MR-MT28
MS-MT28
Australia
USA
France
SC1
SC2
Continent
Americas
Asia
Europe
Oceania
Resistance
MR
MS
PRN
prn2
prn150
prn-others
Predicted PRN-deficient
D
Resistence
PRN
SC2
BP2642A (C664T),
BP3467 (G1621A),
BP3491 (C318A)
SC1
prn-, BP3197 (G370T)
2016
(2014-2018)
MR-MT28
23S rRNA (A2047G)
BP0685 (G1959A), prn150
2005
2010
2015
2020
2025
E
Effective population size
10⁶
10⁵
10⁴
10³
10²
10
1
0.1
2010
2015
2020